Category: antibody drug

FDA Pulls Authorization for Evusheld, Says It’s Ineffective Against New COVID Mutations

January 27, 2023
antibody drugBusiness & MarketsCCP VirusCompaniesCOVID-19USUS NewsVaccines & SafetyXBB.1.5
0 Comment

Evusheld has become the latest COVID-19 antibody drug to lose federal authorization after it was deemed ineffective against the dominant versions of the virus. The U.S. Food and Drug Administration (FDA) on Thursday withdrew its emergency use authorization for Evusheld, a two-dose cocktail of monoclonal antibodies meant to provide protection to those who have a…

Read More

AstraZeneca’s COVID-19 Prevention Jab Granted Emergency Authorization for Immune Compromised

December 9, 2021
AMERICAantibody drugAstrazenecaCCP VirusCOVID-19Executive BranchPolicies & ImpactsPoliticsUSUS Newsvaccinations
0 Comment

The U.S. Food and Drug Administration (FDA) on Dec. 8 issued an emergency use authorization for an AstraZeneca COVID-19 antibody drug designed to help prevent infection in people with compromised immune systems. The drug, called Evusheld, is a combination of two long-acting synthetic antibodies: tixagevimab and cilgavimab, which are derived from B-cells donated by patients who have recovered from the…

Read More

FDA Grants Eli Lilly’s Experimental COVID-19 Antibody-Drug Emergency Use Authorization

February 10, 2021
AMERICAantibody drugCCP VirusCOVID-19Eli LillyPUBLIC HEALTH INFORMATIONUSUS News
0 Comment

Eli Lilly’s COVID-19 antibody-drug has been granted emergency use authorization by the Food and Drug Administration (FDA), widening access to a therapy that has shown improvement in treating patients with mild to moderate cases of the CCP virus. Data from a late-stage trial last month showed that Eli Lilly’s combination therapy of two antibodies, bamlanivimab and…

Read More